Pharmacogenomic profiling enables the identification of patients most likely to benefit from targeted therapies, ensuring more precise and effective interventions.[25] The presence of BRAF V600E mutations serves as a critical biomarker for selecting appropriate targeted treatments, optimizing therapeutic outcomes while minimizing adverse effects.[20,26,27] Comprehensive molecular profiling of gliomas can further identify additional genetic alterations that might influence therapeutic response. This evidence concerns the gene BRAF and central nervous system cancer.